PET and Optical Imaging of Caveolin-1 in Gastric Tumors
Year: 2023
Type: article
Abstract: High Resolution Image Download MS PowerPoint Slide Previous studies have suggested tumoral caveolin-1 (CAV1) as a predictive biomarker for the response to anti-HER2 antibody drug therapies in gastric tumors. In this study, radiolabeled and fluorescently labeled anti-CAV1 antibodies were developed and tested as an immunoPET or optical imaging agent to detect CAV1 in HER2-positive/CAV1-high NCIN87 gastric tumors. The expression of CAV1 receptors in NCIN87 gastric tumors and nontumor murine organs was determined by Western blot. Binding assays were performed to validate the anti-CAV1 antibody specificity for CAV1-expressing NCIN87 cancer cells. Subcutaneous and orthotopic NCIN87 xenografts were used for PET imaging and ex vivo biodistribution of the radioimmunoconjugate. Additional HER2-PET and CAV1-optical imaging was also performed to determine CAV1 in the HER2-positive tumors. 89 Zr-labeled anti-CAV1 antibody was able to bind to CAV1-expressing NCIN87 cells with a B max value of 2.7 × 10 3 CAV1 receptors/cell in vitro . ImmunoPET images demonstrated the localization of the antibody in subcutaneous NCIN87 xenografts. In the orthotopic model, CAV1 expression was also observed by optical imaging in the HER2-positive tumors previously imaged with HER2-PET. Ex vivo biodistribution analysis further confirmed these imaging results. The preclinical data from this study demonstrate the potential of using CAV1-PET and optical imaging for detecting gastric tumors.
Source: ACS Omega
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,685
Funders: Mallinckrodt Institute of Radiology, School of Medicine, Washington University in St. Louis, American Cancer Society, Elsa U. Pardee Foundation, Breast Cancer Alliance, Foundation for Barnes-Jewish Hospital, Alvin J. Siteman Cancer Center, National Institutes of Health, National Cancer Institute
Awards: G1371255133, G1389837536, G1560612189, Reversing Drug Resistance in Tumors with Clickable Antibody Pairs, G257231127, G4066785695, G4548710132, G5894463464, G6120206497, Acquisition of high-resolution PET/CT preclinical imaging instrument at MIR, G8423058586, G9000006824, G9000148080, G9000166811, G9000266654, G9000302610, Cancer Center Support Grant, Cancer Center Support Grant
OpenAlex ID: W4386768417